PCSK9 pipeline shows signs of saturation

Astrazeneca’s decision last week to can its Ionis-partnered once-monthly PCSK9 inhibitor, ION449, was probably a sensible business move. The project, despite looking competitive on cholesterol lowering, might have had a hard time fitting into a market that already has an even longer-acting option, Novartis’s Leqvio.